{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Antibody",
      "COVID-19",
      "Elecsys",
      "LIAISON",
      "SARS-CoV-2",
      "Serology"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32977117",
  "DateCompleted": {
    "Year": "2020",
    "Month": "12",
    "Day": "18"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "01",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "08",
        "Day": "29"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.diagmicrobio.2020.115197",
      "S0732-8893(20)30574-5"
    ],
    "Journal": {
      "ISSN": "1879-0070",
      "JournalIssue": {
        "Volume": "99",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan"
        }
      },
      "Title": "Diagnostic microbiology and infectious disease",
      "ISOAbbreviation": "Diagn Microbiol Infect Dis"
    },
    "ArticleTitle": "Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19.",
    "Pagination": {
      "StartPage": "115197",
      "MedlinePgn": "115197"
    },
    "Abstract": {
      "AbstractText": [
        "Automated assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) diagnostics have recently come available. We compared the performance of the Elecsys\u00ae Anti-SARS-CoV-2 and LIAISON\u00ae SARS-CoV-2\u202fS1/S2 IgG tests. The seroconversion panel comprised of 120 samples from 13 hospitalized COVID-19 patients. For the sensitivity and specificity testing, samples from COVID-19 outpatients >15\u202fdays after positive nucleic acid amplification test (NAAT) result (n\u202f=\u202f35) and serum control samples collected before the COVID-19 era (n\u202f=\u202f161) were included in the material. Samples for the detection of possible cross-reactions were also tested. Based on our results, the SARS-CoV-2 antibodies can be quite reliably detected 2\u202fweeks after NAAT positivity and 3\u202fweeks after the symptom onset with both tests. However, since some COVID-19 patients were positive only with Elecsys\u00ae, the antibodies should be screened against N-antigen (Elecsys\u00ae) and reactive samples confirmed with S antigen (LIAISON\u00ae), but both results should be reported. In some COVID-19 patients, the serology can remain negative."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020 Elsevier Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland. Electronic address: heini.flinck@fimlab.fi."
          }
        ],
        "LastName": "Flinck",
        "ForeName": "Heini",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland."
          }
        ],
        "LastName": "Rauhio",
        "ForeName": "Anne",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland."
          }
        ],
        "LastName": "Luukinen",
        "ForeName": "Bruno",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland."
          }
        ],
        "LastName": "Lehtim\u00e4ki",
        "ForeName": "Terho",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland."
          }
        ],
        "LastName": "Haapala",
        "ForeName": "Anna-Maija",
        "Initials": "AM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland."
          }
        ],
        "LastName": "Seiskari",
        "ForeName": "Tapio",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland."
          }
        ],
        "LastName": "Aittoniemi",
        "ForeName": "Janne",
        "Initials": "J"
      }
    ],
    "PublicationTypeList": [
      "Comparative Study",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Diagn Microbiol Infect Dis",
    "NlmUniqueID": "8305899",
    "ISSNLinking": "0732-8893"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Coronavirus Nucleocapsid Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Phosphoproteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "nucleocapsid phosphoprotein, SARS-CoV-2"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "blood"
      ],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [
        "blood",
        "diagnosis",
        "immunology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Nucleic Acid Testing"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "COVID-19 Serological Testing"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Coronavirus Nucleocapsid Proteins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cross Reactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Kinetics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Phosphoproteins"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology",
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sensitivity and Specificity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Seroconversion"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Young Adult"
    }
  ],
  "CoiStatement": "Conflict of interest No conflict of interest."
}